Navigation Links
Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for MDV3100
Date:10/26/2009

SAN FRANCISCO, Oct. 26 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference at 8:30 a.m. Eastern Time tomorrow, Tuesday, October 27, to discuss partnering plans for MDV3100, Medivation's investigational drug which is currently in Phase 3 testing for the treatment of prostate cancer.

Teleconference/Webcast Details

To participate in the live call on Tuesday, October 27, at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), please dial 888-280-4443 for domestic callers and 1-719-457-2638 for international callers. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, Medivation is conducting a broad dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer's medications in patients with mild, moderate and severe Alzheimer's disease. The companies are also conducting a Phase 3 trial of dimebon in Huntington disease. A Phase 3 clinical trial of MDV3100 in patients with castration-resistant prostate cancer is under way. For more information, please visit us at http://www.medivation.com.

SOURCE Medivation


'/>"/>
SOURCE Medivation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Medivation Announces Participation in Upcoming Conferences
2. Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 CONNECTION Trial of Dimebon in Patients With Alzheimers Disease
3. Medivation Announces Pricing of Public Offering
4. Medivation Announces First Quarter 2009 Financial Results Teleconference and Webcast on May 11, 2009
5. Medivation Announces Upcoming Scientific Presentations at Medical Conferences
6. Medivation Reports Fourth Quarter and Year-End 2008 Financial Results and Provides Corporate Update
7. Medivation Announces New Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
8. Medivation Presents New Data on Dimebons Novel Mechanism of Action
9. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
10. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
11. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... ... Thai delegation at BIO 2016 in San Francisco. Located at booth number 7301, ... available to answer questions and discuss the Thai biotechnology and life sciences sector. ...
(Date:5/25/2016)... ... 2016 , ... The American Medical Informatics Association (AMIA) responded ... Coordinator for Health IT (ONC) outlining a measurement approach to interoperability that focuses ... and where it was needed. The organization of health informatics professionals said a ...
(Date:5/25/2016)... Melbourne, FL (PRWEB) , ... May 25, 2016 , ... ... of eight she tore her cruciate ligament in her left knee. Lady’s owner Hannah ... , a central Florida board-certified veterinary surgeon, to repair her cruciate ligament and help ...
(Date:5/24/2016)... Israel , May 24, 2016   MedyMatch Technology ... physicians with artificial intelligence, real-time decision support tools in the ... present at the 2016 Israeli Advanced Technology Industries (IATI) BioMed ... Israel,s 15th National Life Sciences and ... at the David Intercontinental Hotel in Tel Aviv, ...
Breaking Biology Technology:
(Date:3/14/2016)... -- NXTD ) ("NXT-ID" or the "Company"), a ... airing of a new series of commercials on Time Warner ... st .  The commercials will air on Bloomberg TV, Fox ... Street show. --> NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ...
(Date:3/10/2016)... , March 10, 2016 ... market research report "Identity and Access Management Market by ... Compliance, and Governance), by Organization Size, by Deployment, by ... published by MarketsandMarkets, The market is estimated to grow ... Billion by 2020, at a Compound Annual Growth Rate ...
(Date:3/9/2016)... 9, 2016  Crossmatch ® , a leading ... today announced the addition of smart features to ... multi-factor authentication platform. New contextual and application-specific authentication ... security where it,s needed most — while minimizing ... . --> Washington, DC ...
Breaking Biology News(10 mins):